Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma

NCT02272686 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Slow Accrual

Conditions

Lymphoma

Interventions

DRUG: Ibrutinib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]